Welcome to our dedicated page for Sana Biotechnology news (Ticker: SANA), a resource for investors and traders seeking the latest updates and insights on Sana Biotechnology stock.
Sana Biotechnology, Inc. (SANA) is a leading developer of engineered cell therapies targeting complex diseases through innovative gene editing and immune evasion technologies. This resource provides centralized access to official press releases, clinical trial milestones, and strategic updates from the company.
Investors and industry observers will find timely updates on SANA's hypoimmune (HIP) platform progress, allogeneic CAR T-cell therapy developments, and advancements in diabetes/autoimmune disease research. The curated news collection includes regulatory filings, partnership announcements, and financial results essential for tracking this biotechnology innovator.
Key content categories include clinical trial phases, scientific publications, manufacturing expansions, and intellectual property developments. All materials are sourced directly from company disclosures to ensure accuracy and compliance with financial reporting standards.
Bookmark this page for streamlined monitoring of SANA's progress in creating off-the-shelf cellular medicines. Check back regularly for verified updates on their pipeline targeting oncology, diabetes, and central nervous system disorders.
Sana Biotechnology, Inc. (NASDAQ: SANA) announced its participation in the Cowen 43rd Annual Health Care Conference, scheduled for March 8, 2023, at 9:50 a.m. ET. The presentation will be led by CEO Steve Harr and will provide insights into the company's business strategy and developments in engineered cell therapies. Interested parties can access the live webcast via Sana's Investor Relations page, with a replay available for 30 days post-conference. Sana aims to revolutionize disease treatment through engineered cells, with operations in key U.S. cities including Seattle and Cambridge.
Sana Biotechnology, Inc. (NASDAQ: SANA) will present at the Guggenheim Healthcare Talks 5th Annual Oncology Conference on February 9, 2023, at 1:00 p.m. ET. The presentation, led by CEO Steve Harr, will offer a business overview and update. Interested parties can access the live webcast on Sana's Investor Relations page and view a replay for 30 days post-conference. Founded to create engineered cell therapies, Sana aims to revolutionize disease treatment. The company operates in Seattle, Cambridge, South San Francisco, and Rochester.
Sana Biotechnology (NASDAQ: SANA) announced FDA clearance for its SC291 Investigational New Drug (IND) application, allowing a first-in-human study focusing on B-cell malignancies. SC291, a CD19-targeted allogeneic CAR T cell therapy, utilizes Sana's hypoimmune platform designed to evade immune rejection, potentially increasing treatment efficacy. The company aims to report initial clinical data later this year and is also working on a second IND for SC262, targeting CD22. CEO Steve Harr emphasized the importance of SC291 in providing new options for difficult cancers and highlighted the platform's broader applications, including treatments for type 1 diabetes.
Sana Biotechnology (NASDAQ: SANA) announced its participation in the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 3:45 p.m. PT. CEO Steve Harr will provide a business overview during the webcast, accessible via Sana's Investor Relations page. A replay will be available for 30 days. Sana focuses on engineered cell therapies aimed at repairing and controlling genes and replacing damaged cells. The company operates in Seattle, Cambridge, South San Francisco, and Rochester.
Sana Biotechnology (NASDAQ: SANA) presented data at the 64th American Society of Hematology Annual Meeting, showcasing advancements in its hypoimmune CAR T cell programs. The HIP platform, designed to evade immune detection, demonstrated efficacy in eradicating CD19+ tumors in preclinical models. Key highlights included the scalable production of CAR T cells using CRISPR/Cas12b and promising results for dual-targeted therapies against BCMA and CD19. Sana plans to file three IND applications in the coming years, starting with SC291 targeting CD19-positive cancers in 2023.
Sana Biotechnology (NASDAQ: SANA) has announced a strategic portfolio prioritization aimed at optimizing clinical development and maintaining a strong cash runway into 2025. The company anticipates filing Investigational New Drug (IND) applications for SC291, SG295, and SC263 in 2023, while SC451 and a BCMA-targeted CAR T candidate are scheduled for 2024. However, internal investment in the SC187 program will be discontinued, resulting in a 15% workforce reduction. The firm remains committed to advancing its key clinical programs and improving its engineered cell therapies for serious diseases.
Sana Biotechnology (NASDAQ: SANA) announced that it will present six abstracts, including two oral presentations, at the upcoming 64th American Society of Hematology Annual Meeting from December 10-13, 2022, in New Orleans, LA. The presentations will highlight the potential of Sana's allogeneic CAR T cell and in vivo delivery platforms for treating hematologic malignancies. Key topics include CD19, CD22, and BCMA-targeted therapeutics. The company aims to advance therapies for lymphoma, leukemia, and multiple myeloma, with a focus on innovative approaches to enhance therapeutic efficacy.
Sana Biotechnology, Inc. (NASDAQ: SANA) reported Q3 2022 results, highlighting a cash position of $511.6 million. The company expects to file IND applications for SC291 and SC276 in 2023, with clinical data following. Research and development expenses rose significantly to $76.7 million due to increased headcount and third-party manufacturing costs. Net loss for the quarter was $85.1 million, slightly worse than in 2021. Despite these losses, Sana maintains a robust cash runway into 2025, supporting ongoing development of its innovative CAR T therapies and hypoimmune platform.
Cellarity, a life sciences company, announced the successful completion of a $121 million Series C financing, raising total funds to $274 million. This round attracted new investors, including Kyowa Kirin Co. Ltd and Hanwha Impact Partners, alongside existing backers. The funds will be used to expand talent, enhance its platform, and progress its drug pipeline. Cellarity’s innovative approach focuses on cellular dysfunction rather than targeting individual molecules, aiming for breakthroughs in treating various diseases.
FAQ
What is the current stock price of Sana Biotechnology (SANA)?
What is the market cap of Sana Biotechnology (SANA)?
